The Latest Cardiac and Vascular News
Irvine, CA (April 9, 2024) – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced three-month follow-up results from the SmartfIRE clinical trial, unveiled in a late-breaking presentation by Dr. Tom De Potter,i an investigator in the study, during the annual meeting […]
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company’s Deep Learning Technology Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables April 09, 2024 08:31 AM […]
AUSTIN, Texas, April 9, 2024 /PRNewswire/ — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial…
EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology,…
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, a pioneer in non-invasive, AI-based arrhythmia analysis technology, today announced the publication of data in the Journal of Cardiovascular Electrophysiology (JACE) demonstrating vMap’s ability to reduce the time from mapping to treatment, procedure duration, and fluoroscopy when treating cardiac arrhythmia patients with ablation therapy. “A 22.6% reduction in […]
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular tachycardia (PSVT).
LAGUNA HILLS, Calif., March 25, 2024 /PRNewswire/ — Adagio Medical, Inc., a leading innovator in catheter ablation technologies for ventricular tachycardia (“VT”) and atrial fibrillation (“AF”), today announced CE Mark approval of its ultra-low temperature cryoablation (“ULTC”) system for the treatment of monomorphic ventricular tachycardia. The system consists of the upgraded cryoablation console, […]
EPLive 2024 is a two-day conference that draws the world’s top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ — On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host its seventh international…
Findings from the admIRE study – freedom from atrial arrhythmia recurrence at 12 months – support the submission of the VARIPULSE™ Platform among U.S. patients IRVINE, Calif., March 25, 2024 /PRNewswire/ — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part…
BRAINTREE, Mass., March 22, 2024 /PRNewswire/ — PrepMD, the leading provider of cardiac healthcare solutions, and Magnifi Group, Inc., renowned for its educational courses for Orthopedic Fellows, today announced partnership to create and manage an innovative annual Electrophysiology (EP)…
